New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, ...

Unlike today's crop of commercially approved CAR-T therapies that rely on viral vectors, GenomeFrontier is pursuing a ...

Consumer drug behemoth Reckitt is dropping $600 million on a multi-year revamp of its U.S. operations. The health and hygiene ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...

Legend Biotech has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth. Zhang officially took the Legend CEO title on Sept. 15, ...

As one of the chief players in the automated cell therapy manufacturing space grapples with a recent setback, another is ...

Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...

In a push to free itself up for more R&D, Sanofi is acquiring a stake in German drugmaker, Cheplapharm. | In a deal that ...

BioMarin is pumping the brakes on yet another indication for its CNP analogue, Voxzogo. | The rare disease biotech announced ...

In what signifies the end of a challenging regulatory journey, Scholar Rock secured an FDA approval for its spinal muscular ...

GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...

GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.  | GSK is ...